Curis, Inc. (CRIS) Price Prediction 2026–2050

Curis, Inc. is a biotechnology company that engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its pipeline includes Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma.

The company’s other programs include Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule TIM3/PD-L1 antagonist. It has collaboration agreements with Genentech Inc. and Roche for the commercialization of Erivedge, an orally-administered hedgehog pathway antagonist for advanced basal cell carcinoma; Aurigene Discovery Technologies Limited for discovery, development, and commercialization in immuno-oncology and precision oncology; and it licensed three programs under the Aurigene collaboration, including emavusertib.

Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Curis, Inc. (CRIS) is a biotechnology company focused on developing cancer therapies. The stock is trading at $0.5012 with a market capitalization of $19.54M and a market rank of 4949. The current price sits within a broader forecast that envisions mixed near-term movement but meaningful upside in the longer term.

Forecast data show a path from a 2026 average near the current price toward higher targets by the end of the decade and into the 2040s and 2050s, with estimated max prices extending to $3.36 by 2050. The near term includes neutral sentiment, while later years turn bullish, suggesting potential upside despite a modest starting point. The forecasted averages range from roughly $0.48 in 2026 to $0.6396 in 2030, up to $1.56 in 2050, with corresponding ROIs spanning from 0% to 210.9%.

The multi-year forecast shows a transition from neutral to bullish sentiment over time. In 2030, the average price is forecast at $0.6396 with a min of $0.4361 and a max of $1.02, and a bullish ROI of 27.6%. The outlook improves further into 2040, with an average of $0.7734, a max of $1.49, a bullish ROI of 54.3%, and bullish sentiment.

By 2050, the forecast calls for an average of $1.56, a min of $0.7013, a max of $3.36, and a bullish ROI of 210.9%.

These figures point to potential upside over the long term, but they come with uncertainty and are not guarantees. The forecast shows higher upside in later years while early years may remain subdued or mixed in sentiment.